24 completed, 10 terminated, 4 recruiting, 4 unknown. 45 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 45 | Completed 24, Terminated 10, Recruiting 4, Unknown 4, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 14 | Completed 9, Terminated 4, Not yet recruiting 1 |
Follow Myeloma: new trials by email Literature Review of Myeloma trials Research Report on Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors Dose Level -1, Dose Level 1 (starting dose level), Dose Level 2 - Lymphoma, Myeloma | Phase 1 | Withdrawn | Baylor College of Medicine | 2026-06-01 | 2026-09-16 | |
| ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma Elotuzumab, Iberdomide, Dexamethasone - Myeloma, Multiple Myeloma | Phase 1 | Recruiting | Omar Nadeem, MD | 24 | 2024-11-01 | 2026-11-02 |
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) - Multiple Myeloma, Myeloma | Phase 1 | Recruiting | K36 Therapeutics, Inc. | 165 | 2023-02-22 | 2026-10-22 |
| Pilot Imaging Study of Leukemia FLT - Acute Lymphocytic Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Oklahoma | 60 | 2023-01-19 | 2026-04-23 |
| Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients 18F-Fludarabine - Myeloma | Phase 1 | Unknown | Nantes University Hospital | 35 | 2022-09-09 | 2024-06-14 |
| A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma Belantamab mafodotin - Myeloma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 30 | 2022-05-18 | 2026-06-11 |
| Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy BMS-986345, Duvelisib - Non Hodgkin Lymphoma, Hodgkin Lymphoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 14 | 2021-11-18 | 2025-12-04 |
| FT576 in Subjects With Multiple Myeloma FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine - Multiple Myeloma, Myeloma | Phase 1 | Completed | Fate Therapeutics | 31 | 2021-11-10 | 2025-12-12 |
| Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies Autologous CAR-T cells, Fludarabine, Cyclophosphamide - Relapsed/Refractory Hematological Malignancies, Lymphoma | Phase 1 | Unknown | The Affiliated People's Hospital of Ningbo University | 10 | 2021-09-16 | 2022-09-06 |
| FT538 in Subjects With Advanced Hematologic Malignancies FT538, Cyclophosphamide, Fludarabine - Acute Myeloid Leukemia, AML, Adult | Phase 1 | Terminated | Fate Therapeutics | 42 | 2020-10-17 | 2023-09-21 |
| Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation Celrixafor - Lymphoma, Myeloma | Phase 1 | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 6 | 2019-12-09 | 2025-03-27 |
| Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation CD62L- Tem - Lymphoma, Leukemia | Phase 1 | Unknown | University College, London | 18 | 2019-10-21 | 2019-10-25 |
| Positron Emission Tomography (PET) Imaging Studies With NIS Reporter BF4 - Myeloma, Endometrial Cancer | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 8 | 2016-09-01 | 2019-05-17 |
| Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma DS-3032b - Myeloma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 14 | 2016-08-30 | 2019-11-15 |
| Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma Clarithromycin, Dexamethasone, Ixazomib Citrate - Myeloma | Phase 1 / Phase 2 | Completed | Joseph Tuscano | 32 | 2015-10-22 | 2026-11-02 |
| Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis Pomalidomide, Melphalan, Dexamethasone - Myeloma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 3 | 2014-01-01 | 2016-05-13 |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene Fludarabine, Melphalan, Alemtuzumab - Leukemia, Myeloma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2013-12-27 | 2019-07-16 |
| Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma Lenalidomide, Dexamethasone, All-Trans Retinoic Acid (ATRA) - Myeloma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 2 | 2013-12-01 | 2016-09-14 |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT ALT-803 - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 1 / Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 33 | 2013-11-11 | 2020-08-12 |
Showing 20 of 45. Sign in to see all of them.
Neoplasms, Plasma Cell (45) · Lymphoma (21) · Multiple Myeloma (15) · Leukemia (13) · Hodgkin Disease (7) · Myelodysplastic Syndromes (6) · Graft vs Host Disease (4) · Leukemia, Myeloid, Acute (4) · Lymphoma, Non-Hodgkin (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Hematologic Neoplasms (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Recurrence (3) · Sarcoma (2) · Amyloidosis (1)
Neoplasms (45) · Neoplasms by Histologic Type (45) · Hemic and Lymphatic Diseases (35) · Immune System Diseases (35) · Immunoproliferative Disorders (35) · Lymphoproliferative Disorders (35) · Hematologic Diseases (31) · Lymphatic Diseases (23) · Blood Protein Disorders (15) · Cardiovascular Diseases (15) · Hemorrhagic Disorders (15) · Hemostatic Disorders (15) · Paraproteinemias (15) · Vascular Diseases (15) · Bone Marrow Diseases (8)
Dexamethasone (10) · Melphalan (9) · fludarabine (9) · Calcium Dobesilate (7) · Lenalidomide (7) · Cyclophosphamide (6) · Bortezomib (5) · Radiotherapy (5) · Surveys and Questionnaires (4) · fludarabine phosphate (4) · pomalidomide (4) · Alemtuzumab (3) · Stem Cell Transplantation (3) · Bendamustine Hydrochloride (2) · Busulfan (2)
M.D. Anderson Cancer Center (12) · University of Chicago (3) · Baylor College of Medicine (2) · Fate Therapeutics (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Nantes University Hospital (2) · Bayside Health (1) · Dana-Farber Cancer Institute (1) · Duke University (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Joseph Tuscano (1) · K36 Therapeutics, Inc. (1) · Masonic Cancer Center, University of Minnesota (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1)
United States (34) · France (3) · Canada (2) · United Kingdom (2) · Australia (1) · China (1) · Germany (1) · Mexico (1) · Singapore (1) · Spain (1)
Jatin J. Shah, MD (2) · Muzaffar H. Qazilbash, MD (2) · Andrew Artz, M.D. (1) · Andrew Artz, MD (1) · Andrew Spencer, MBChB, FRACP, PhD (1) · Armand Keating, MD (1) · Bilal Omer, MD (1) · Brigitte Kolb (1) · Carine Chaleteix (1) · Carlos Ramos, MD (1) · Cyril Hulin (1) · Denis Caillot (1) · Dolores Grosso, DNP, CRNP (1)
PMID 16040380, PMID 17896890, PMID 18283630, PMID 20919852, PMID 22451423, PMID 23100308, PMID 25784682, PMID 26932802, PMID 27270177, PMID 29463563, PMID 30501870, PMID 31618456, PMID 31940591, PMID 33951890, PMID 35303007, PMID 38867006, PMID 40948663, PMID 42545812
2025 (1), P30CA006516 (1)